Skip to main content
. 2019 Jul 10;21(8):1159–1166. doi: 10.1093/europace/euz175

Figure 3.

Figure 3

(A) Relative risks of sustained conversion at 24 h in trials comparing vernakalant to comparator in patients with recent-onset atrial fibrillation: all participants. (B) Relative risks of sustained conversion at 24 h in trials comparing vernakalant to comparator in patients with recent-onset atrial fibrillation: participants who converted acutely.